Scynexis Inc financial data

Symbol
SCYX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1 Evertrust Plaza, 13 Th Floor, Jersey City, New Jersey
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 624 % +58.6%
Quick Ratio 25.8 % +354%
Debt-to-equity 65.6 % -93.6%
Return On Equity 122 %
Return On Assets 73.7 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37.8 M shares +13.3%
Common Stock, Shares, Outstanding 37.8 M shares +13.4%
Entity Public Float 60.2 M USD -64.4%
Weighted Average Number of Shares Outstanding, Basic 48.2 M shares +1.02%
Weighted Average Number of Shares Outstanding, Diluted 48.6 M shares +1.69%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.37 M USD +21.5%
Research and Development Expense 31.3 M USD +10.4%
Operating Income (Loss) 73.8 M USD +11%
Nonoperating Income (Expense) 28.2 M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 102 M USD
Income Tax Expense (Benefit) 669 K USD
Net Income (Loss) Attributable to Parent 101 M USD
Earnings Per Share, Basic 2.12 USD/shares
Earnings Per Share, Diluted 2.11 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.5 M USD +31.8%
Cash, Cash Equivalents, and Short-term Investments 94.2 M USD +71.9%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Inventory, Net 0 USD -100%
Other Assets, Current 556 K USD +91.1%
Assets, Current 102 M USD +70.1%
Property, Plant and Equipment, Net 61 K USD -77.5%
Operating Lease, Right-of-Use Asset 2.3 M USD -9.45%
Intangible Assets, Net (Excluding Goodwill) 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 118 M USD +68.2%
Accounts Payable, Current 8.92 M USD +50.5%
Accrued Liabilities, Current 4.6 M USD -3.64%
Liabilities, Current 27.3 M USD -40.1%
Operating Lease, Liability, Noncurrent 2.49 M USD -12.5%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 44.1 M USD -55.9%
Retained Earnings (Accumulated Deficit) -355 M USD +22.2%
Stockholders' Equity Attributable to Parent 74.1 M USD
Liabilities and Equity 118 M USD +68.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.01 M USD +78.8%
Net Cash Provided by (Used in) Financing Activities 22 K USD -99.7%
Net Cash Provided by (Used in) Investing Activities 5.45 M USD
Common Stock, Shares Authorized 150 M shares 0%
Common Stock, Shares, Issued 37.8 M shares +13.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 36 M USD +32.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 420 K USD -74.7%
Deferred Tax Assets, Valuation Allowance 60.6 M USD -41.4%
Deferred Tax Assets, Gross 60.6 M USD -41.4%
Operating Lease, Liability 2.84 M USD -9.4%
Lessee, Operating Lease, Liability, to be Paid 4.08 M USD -15%
Operating Lease, Liability, Current 356 K USD +20.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 759 K USD +2.02%
Lessee, Operating Lease, Liability, to be Paid, Year One 744 K USD +1.92%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.24 M USD -25.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 774 K USD +1.98%
Deferred Tax Assets, Operating Loss Carryforwards 46.4 M USD -47.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5 M shares 0%
Unrecognized Tax Benefits 361 K USD -17.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 790 K USD +2.07%
Operating Lease, Payments 719 K USD +35.7%
Additional Paid in Capital 429 M USD +0.63%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 2.62 M USD -20.5%
Interest Expense 1.89 M USD -66.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%